Search results for "Fibrosis"

showing 10 items of 901 documents

Novel tricyclic pyrrolo-quinolines as pharmacological correctors of the mutant CFTR chloride channel

2023

AbstractF508del, the most frequent mutation in cystic fibrosis (CF), impairs the stability and folding of the CFTR chloride channel, thus resulting in intracellular retention and CFTR degradation. The F508del defect can be targeted with pharmacological correctors, such as VX-809 and VX-445, that stabilize CFTR and improve its trafficking to plasma membrane. Using a functional test to evaluate a panel of chemical compounds, we have identified tricyclic pyrrolo-quinolines as novel F508del correctors with high efficacy on primary airway epithelial cells from CF patients. The most effective compound, PP028, showed synergy when combined with VX-809 and VX-661 but not with VX-445. By testing the …

Multidisciplinarypyrrolo‑quinolinesCFTRSettore CHIM/08 - Chimica FarmaceuticaCystic fibrosisScientific Reports
researchProduct

P.20.3 Targeting fibrosis and inflammation in Duchenne Muscular Dystrophy

2013

Duchenne Muscular Dystrophy is the most frequent genetic muscle disease worldwide affecting ∼1:5000 male births. It is caused by a defective DMD gene, which leads to reduced and defective dystrophin protein expression. The constant breakdown of fibres leads to focal necrosis, myophagocytosis and a considerable influx of inflammatory cells into the muscle tissue, which is followed by increasing endomysial fibrosis. Both, inflammation and fibrosis as well as a putative relation are not yet understood immunologically. Fibrosis directly correlates with adverse outcome and early loss of ambulation. We have studied how inflammation is linked to fibrosis in DMD, with an emphasis on the communicati…

Muscle biopsymedicine.diagnostic_testbiologyDuchenne muscular dystrophyInflammationDiseasemedicine.diseasePhenotypeImmune systemNeurologyFibrosisPediatrics Perinatology and Child HealthImmunologymedicinebiology.proteinNeurology (clinical)medicine.symptomDystrophinGenetics (clinical)Neuromuscular Disorders
researchProduct

Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations.

2009

Chromosome 1 is the largest human chromosome and contains over 1600 known genes and 1000 novel coding sequences or transcripts. It is, therefore, not surprising that recurrent chromosome 1 abnormalities are regularly encountered in both neoplastic and non-neoplastic medical conditions. The current review is focused on myeloid malignancies where we summarize the relevant published literature and discuss specific karyotype-phenotype associations. We show that chromosome 1 abnormalities are most frequent in BCR-ABL-negative classic myeloproliferative neoplasms (MPN): polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Specific abnormalities include duplicat…

MyeloidChromosomal translocationBiologyTranslocation GeneticSettore MED/15 - Malattie Del Sanguehemic and lymphatic diseasesmedicineHumansGenes Tumor SuppressorMyelofibrosisGeneticsChromosome AberrationsMyeloproliferative DisordersEssential thrombocythemiaMyelodysplastic syndromesMyeloid leukemiaKaryotypeHematologyGeneral MedicineOncogenesmedicine.diseasemedicine.anatomical_structurePhenotypeChromosomes Human Pair 1Leukemia MyeloidKaryotypingMyelodysplastic Syndromeschomosome 1 myeloid malignancyChromosome DeletionLiterature surveyEuropean journal of haematology
researchProduct

Role of heat shock protein in myeloproliferative neoplasms : involvement of HSP27 in myelofibrosis

2017

Myelofibrosis (MF) is the most aggressive myeloproliferative neoplasms (MPN) with the highest degree of morbidity and mortality, including progressive bone marrow fibrosis resulting into bone marrow failure. JAK2 kinase inhibitors have been successfully used for a few years in MPN and more particularly for MF treatment. Nevertheless, their beneficial effects are mainly restricted on symptoms and not on the course of the disease. Recently, heat shock protein 90 (HSP90) - known to stabilize JAK2 - has been reported as a promising therapeutic target in MPN. However HSP90 inhibitors show toxicity and induce the expression of stress-inducible proteins such as HSP70 and, most likely HSP27 as prev…

Myélofibrose[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyHeat shock proteinMyelofibrosisProtéines de choc thermiqueThérapieHSP27Therapy
researchProduct

Reply to: “Is industrial fructose just a marker of an unhealthy dietary pattern?”

2014

We recently reported a link between fructose intake and the severity of liver fibrosis in a cohort of Italian patients with genotype 1 (G1) chronic hepatitis C (CHC) [1]. In particular, the association holds true for ‘‘industrial’’ only, not for ‘‘fruit’’ fructose intake. We thank Chiavaroli and colleagues for their comments that give us the opportunity to further strengthen data from our analyses.

NAFLD FRUCTOSE HCV FIBROSISSteatosisHepatologybusiness.industryMEDLINELiver fibrosiFructoseDietary patternHepatitis Cchemistry.chemical_compoundchemistryMedicineFood sciencebusinessJournal of Hepatology
researchProduct

The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care

2020

Background & Aims NAFLD is a growing health concern. The aim of the Fatty Liver Assessment in Germany (FLAG) study was to assess disease burden and provide data on the standard of care from secondary care. Methods The FLAG study is an observational real-world study in patients with NAFLD enrolled at 13 centres across Germany. Severity of disease was assessed by non-invasive surrogate scores and data recorded at baseline and 12 months. Results In this study, 507 patients (mean age 53 years; 47% women) were enrolled. According to fibrosis-4 index, 64%, 26%, and 10% of the patients had no significant fibrosis, indeterminate stage, and advanced fibrosis, respectively. Patients with advanced fib…

NAFLD non-alcoholic fatty liver diseasemedicine.medical_specialtyBMI body mass indexNASH non-alcoholic steatohepatitisLiver fibrosisLSM liver stiffness measurementAST aspartate aminotransferaseLiver diseaseFLAG Fatty Liver Assessment in GermanyNAFLDALT alanine aminotransferaseInternal medicineAPRI aspartate-aminotransferase-to-platelet ratio indexInternal MedicineNAFL non-alcoholic fatty liverImmunology and AllergyMedicineddc:610Co-morbiditieslcsh:RC799-869FIB-4 fibrosis-4Disease burdenHepatologyFAST FibroScan-ASTGGT gamma-glutamyltransferasebusiness.industryFatty liverNASHGastroenterologyReal worldGLP-1 glucagon-like peptide-1T2DM type 2 diabetes mellitusCVE cardiovascular eventmedicine.diseaseMetabolic syndromeCohortlcsh:Diseases of the digestive system. GastroenterologyCAP controlled attenuation parameterSteatohepatitisMetabolic syndromebusinessBody mass indexResearch ArticleCohort studyJHEP Reports
researchProduct

Reply

2017

NASH FIBROSIS STIFFNESS0301 basic medicineSettore MED/12 - Gastroenterologia03 medical and health sciences030104 developmental biology0302 clinical medicineHepatologybusiness.industryMedicine030211 gastroenterology & hepatologybusinessHepatology
researchProduct

Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis

2021

Background & Aims Progressive fibrosis has been identified as the major predictor of mortality in patients with non-alcoholic fatty liver disease (NAFLD). Several biomarkers are currently being evaluated for their ability to substitute the liver biopsy as the reference standard. Recent clinical studies in NAFLD/NASH patients support the utility of PRO-C3, a marker of type III collagen formation, as a marker for the degree of fibrosis, disease activity, and effect of treatment. Here we establish the healthy reference range, optimal sample handling conditions for both short- and long-term serum storage, and robustness for the PRO-C3 assay. Methods PRO-C3 was measured in 269 healthy volunteers…

NASH-CRN NASH Clinical Research NetworkBiopsyDiseaseAST aspartate aminotransferaseRC799-869Ethnic groupsGastroenterologyNIMBLE Non-Invasive Biomarkers of Metabolic Liver Disease (consortium)FibrosisImmunology and AllergyBody mass indexmedicine.diagnostic_testFatty liverNAS NAFLD Activity ScoreGastroenterologyDiseases of the digestive system. GastroenterologyHospitalsNPV negative predictive valueLiver biopsyBiomarker (medicine)Research Articlemedicine.medical_specialtyNAFLD non-alcoholic fatty liver diseaseADAM A Disintegrin and MetalloproteasesNASH non-alcoholic steatohepatitisReference rangeReference valuesAUROC area under the receiver operating characteristics curveInternal medicineALT alanine aminotransferaseBiopsyInternal MedicinemedicineHumansFIB-4 fibrosis-4Healthy volunteersHepatologyALP alkaline phosphatasebusiness.industryCLSI Clinical and Laboratory Standards InstituteT2DM type 2 diabetes mellitusELF™ test Enhanced Liver Fibrosis testmedicine.diseaseLITMUS Liver Investigation: Testing Marker Utility in Steatohepatitis (consortium)Collagen type IIIFibrosisPPV positive predictive valueReference standardsbusinessBody mass indexBiomarkersNon-alcoholic fatty liver disease
researchProduct

Staphylococcal Biofilms:Challenges in the Discovery of Novel Antiinfective Agents

2011

Staphylococci can induce a wide spectrum of infectious diseases that are associated with remarkable morbidity and mortality [1]. In fact, community and hospital-acquired methicillin resistant Staphylococcus aureus (MRSA) is a major health problem that has created a pressing need for novel therapeutic options [2]. Importantly, pathogenic staphylococci have not only an amazing ability to acquire resistance to antibiotics, but also to form biofilms, bacterial communities that grow on surfaces and are surrounded by a self-produced polymer matrix. This latter characteristic is likely the most important virulence factor of staphylococci in the development of the chronic form of infectious disease…

Native Valve Endocarditismedicine.drug_classOsteomyelitisAntibioticsBiofilmBiologymedicine.diseasemedicine.disease_causeApplied Microbiology and BiotechnologyBiochemistryMicrobiologyMethicillin-resistant Staphylococcus aureusCystic fibrosisMicrobiologyOtitismedicineSeptic arthritismedicine.symptomBiotechnologyJournal of Microbial & Biochemical Technology
researchProduct

Xenotransplantation of parathyroids in rats using barium-alginate and polyacrylic acid multilayer microcapsules

2001

The integrity and function of encapsulated parathyroid tissue following xenotransplantation is limited by oxygen and nutrition supply and capsule fibrosis. Since some of these factors depend on stability and biocompatibility of the coating material, multilayer microcapsules have been developed. Parathyroid tissue pieces and digested single cells from pigs were encapsulated in barium-alginate and in polyacrylic acid (PAA) multilayer capsules. After 7 days of culture the function of the encapsulated cells were assessed. Subsequently, in a part of the cultured microcapsules the viability was directly assessed whereas the other part was transplanted in dark animal [DA] rats for 30 days. After e…

NecrosisBiocompatibilityAlginatesCell SurvivalSwineBarium CompoundsTransplantation HeterologousAcrylic ResinsConnective tissueParathyroid hormoneToxicologyPathology and Forensic MedicineParathyroid Glandschemistry.chemical_compoundDrug Delivery SystemsCoated Materials BiocompatibleGlucuronic AcidIn vivoFibrosismedicineAnimalsCells CulturedChemistryHexuronic AcidsGraft SurvivalCapsuleCell BiologyGeneral MedicineAnatomymedicine.diseaseGlucuronic acidMolecular biologyRatsmedicine.anatomical_structureParathyroid Hormonemedicine.symptomExperimental and Toxicologic Pathology
researchProduct